Drugs / Octaplasma
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05068830 Comparator | Sep 2021 → Mar 2027 expected | Alzheimer disease | Norwegian University of Science and Technology | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Octaplasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05068830 ↗ |
| Route | Intravenous | “Dosage form: Solution for intravenous infusion” NCT05068830 ↗ |